fertility preservation

providing future reproductive opportunities before a medical treatment

Uses your system voice; voice and rate in settings.

Q5445580Snapshot

≈ 5 min read

Names in other languages

  • Englishfertility preservation
  • DeutschFertilitätsprotektion
  • azFertillik Qorunması
  • العربيةحفظ الخصوبة
  • 日本語妊孕性温存療法
  • 中文生育能力保存
  • 简体中文生育能力保存
  • 繁體中文生育能力儲存

Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.

Fertility preservation is the effort to help cancer patients retain their fertility, or ability to procreate. Research into how cancer, ageing and other health conditions effect reproductive health and preservation options are growing, specifically sparked in part by the increase in the survival rate of cancer patients.

Indications

Fertility preservation procedures are indicated when it is predicted that there will be exposure to a cause of infertility, mainly cancer treatment but also ageing, Gender-affirming hormone therapy (GAHT) for transgender individuals and conditions like Polyendocrine metabolic ovarian syndrome (PMOS) or Primary ovarian insufficiency (POI).

Chemotherapy and radiotherapy

Chemotherapy and radiation treatments for cancer and autoimmune conditions like Lupus and Multiple Sclerosis have the ability to affect reproductive health. The regimens that threaten ovarian and testicular function are mainly radiation therapy to the pelvic area and some types of chemotherapy.

Chemotherapies with high risk include procarbazine and alkylating drugs such as cyclophosphamide, ifosfamide, busulfan, melphalan, chlorambucil and chlormethine. Drugs with medium risk include doxorubicin and platinum analogs such as cisplatin and carboplatin.

On the other hand, therapies with low risk of gonadotoxicity include plant derivatives such as vincristine and vinblastine, antibiotics such as bleomycin and dactinomycin and antimetabolites such as methotrexate, mercaptopurine and 5-fluoruracil. These regimens attack rapidly dividing cells in the body, including healthy cells like sperm and those belonging to the ovarian follicle (egg).

Depending on the dose and duration of administration, these therapies can have varying effects on reproductive health. Surgery involving reproductive tissue affects reproductive function and fertility.

For some patients receiving chemotherapy or radiotherapy, the decrease or loss of reproductive function is temporary; many male and female patients, however, do not regain fertility after this treatment. The extent of the damage to ovaries resulting in diminished fertility can be associated with the chemotherapeutic regiment such as the combination of chemotherapy and radiotherapy (chemoradiation) where despite allowing a more effective treatment or reducing the risk of the cancer returning (adjuvant chemotherapy).

It has extensive associations with fertility damage than receiving either treatment individually. Sometimes these patients experience symptoms resembling menopause (in females) or andropause (in men), which can indicate reproductive damage. In females this can be premature menopause of menopause in premenopausal women; this state can be permanent or reversible, dependent on many factors.

A study indicated that fewer oocytes are recovered from cancer patients wanting to perform embryo preservation when compared with an age-matched control group, but the mean number of zygotes generated appears to be similar. The same study found that, of 65 patients referred to the program, 28% declined to undergo embryo, oocyte, or tissue cryopreservation.

9% were found not to be eligible for medical reasons. Of the remaining 41 patients, 85% chose to cryopreserve embryos, 10% chose to cryopreserve oocytes, and 5% chose to undergo ovarian tissue freezing. No serious clinical sequelae resulted from participation.

Prior to females undergoing these treatments, a testing for the level of anti-Müllerian hormone (AMH) is useful in predicting the long-term post-chemotherapy loss of ovarian function, in turn predicting the need for fertility preservation strategies in the future.

Ageing

Increasing age in females is directly associated with decreasing reproductive potential. This can be the result of many factors such as the amount of eggs available and their overall reproductive quality. Fertility preservation, such as ovarian tissue or oocyte cryopreservation, may also be used to prevent infertility, as well as birth defects, associated with advanced maternal age.

Males also have decreasing fertility as they age, however this is associated with a problem in sperm quality as opposed to the overall sperm count. These changes can be attributed to the reduction in testosterone males experience when ageing.

Methods

The main methods of fertility preservation are ovarian protection by GnRH agonists, cryopreservation of ovarian tissue, eggs or sperm, or of embryos after in vitro fertilization. The patient may also choose to use egg or sperm from a donor by third party reproduction rather than having biological children.

Semen cryopreservation

Men hoping to preserve their fertility before undergoing treatment for cancer or another fertility-threatening disease can cryopreserve, or freeze, their sperm, which can be obtained through masturbation in post-pubescent boys and men. This is the most established fertility preservation method for males.

For pre-pubescent boys, sperm can be obtained through testicular aspiration or electrostimulation and then stored for future use. Researchers are also looking at methods for cryopreserving testicular tissue samples so that they can be re-implanted into the body after treatment.

Third-party reproduction

Many patients diagnosed with a malignancy or another disease requiring treatment that may impair their fertility consider alternatives to bearing biological children, such as assisted reproductive technology (ART) using in vitro fertilization (IVF) with donor eggs or donor sperm. The resulting embryo can be implanted into the female's's uterus after her endometrium (the lining of the uterus) is stimulated with hormones to prepare for the development of the embryo.

Others

Females requiring local pelvic radiation therapy may benefit from surgical transposition of the ovaries to a site remote from maximal radiation exposure. The use of GnRH agonists for ovarian protection during chemotherapy is suggested to benefit the ability to ovulate, but benefits in terms of e.g. pregnancy rate are lacking. Table 1: Main Options of Fertility Preservation

Text derived from https://en.wikipedia.org/w/index.php?oldid=1375414975 under CC BY-SA 4.0; modifications have been made.

Sources cited in this revision

No external citation was extracted for this revision. That is a statement about the source, not a claim that none exists.